Dark

IPSC
Century Therapeutics, Inc. Common Stock
stock NASDAQ

At Close

Oct 2, 2026 3:59:56 PM EDT

1.52USD-5.590%(-0.09)802,950

1.51Bid 1.53Ask 0.02Spread

Pre-market

Oct 1, 2026 9:25:30 AM EDT

1.64USD+1.863%(+0.03)0

After-hours

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 10, 2022

07:02AM EST Century Therapeutics And Bristol Myers Squibb Enter Into A Strategic Collaboration To Develop iPSC-derived Allogeneic Cell Therapies Benzinga

06:59AM EST - Collaboration brings together Centurys industry leading iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibbs expertise in cell therapy and oncology drug development - GlobeNewswire Inc

Jan 4, 2022

04:30PM EST Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30 PM ET. GlobeNewswire Inc

Dec 17, 2021

07:16AM EST Century Therapeutics Reports Will Be Added To Nasdaq Biotech Index, Effective Dec. 20, 2021 Benzinga

07:00AM EST Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective as of market open on Monday, December 20, 2021. GlobeNewswire Inc

Dec 16, 2021

06:30AM EST - In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 - GlobeNewswire Inc

Nov 22, 2021

08:00AM EST Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team have participated in a fireside chat in advance of the Piper Sandler 33rd Annual Virtual Healthcare Conference, being held November 30- December 2, 2021. GlobeNewswire Inc

Nov 19, 2021

07:07AM EST SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $32 Benzinga

Nov 10, 2021

07:49AM EST Century Therapeutics Q3 Net Loss $26M vs Net Loss $13.1M In Same Period Last Year Benzinga

07:44AM EST Century Therapeutics Q3 Loss Per Share $0.48 Vs Loss $1.75 Last Year RTTNews

07:30AM EST Lead program, CNTY-101 in relapsed/refractory non-Hodgkins lymphoma, remains on track for IND filing in mid-2022 GlobeNewswire Inc

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Oct 7, 2021

07:34AM EDT Century Therapeutics And Outpace Bio Enter Research Collaboration In CAR Engineering Benzinga

07:30AM EDT Collaboration enables Century to explore Outpaces protein solutions for cell therapy to enhance functionality of iPSC platform GlobeNewswire Inc

Sep 17, 2021

04:01PM EDT Century Therapeutics Announces Its Addition to the Russell GlobeNewswire Inc

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 13, 2021

07:43AM EDT The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO Benzinga

Aug 12, 2021

08:25AM EDT Century Therapeutics Q2 Net Loss $23.3 Mln Vs Loss $15.3 Mln Last Year RTTNews

08:15AM EDT Century Therapeutics Q2 EPS $(1.93) Up From $(2.05) YoY Benzinga

08:00AM EDT Continued Company investment across our iPSC platforms, programs, and manufacturingLead program, CNTY-101, remains on track for IND filing in mid-2022Recent IPO with net proceeds of approximately $221MJune 30, 2021 cash, cash equivalents, and marketable securities of $440M GlobeNewswire Inc

Jul 23, 2021

07:45AM EDT The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs Benzinga

Jul 13, 2021

05:20PM EDT These 3 New Biotechs Have Differentiated Platforms, Technology: BofA Benzinga

11:50AM EDT B of A Securities Initiates Coverage On Century Therapeutics with Buy Rating, Announces Price Target of $34 Benzinga

10:13AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 Benzinga

09:19AM EDT UPDATE: SVB Leerlink On Century Therapeutics Outperform Initiation: Dependance On External Competitive Catalysts Adds To Risk Profile That Co. Can Mitigate Through The Acceleration Of Their Tumor Treatment Programs To The Public Benzinga

09:15AM EDT UPDATE: SVB Leerlink On Century Therapeutics Outperform Initiation: Induced Pluripotent Cells And Passive Allo-Evasion Are The Foundational Therapies That Firm Thinks Will Prove Transformative After Their Success On Solid Tumor Targeting Benzinga

06:35AM EDT SVB Leerink Initiates Coverage On Century Therapeutics with Outperform Rating, Announces Price Target of $33 Benzinga

05:29AM EDT JP Morgan Initiates Coverage On Century Therapeutics with Overweight Rating, Announces Price Target of $40 Benzinga

05:15AM EDT Piper Sandler Initiates Coverage On Century Therapeutics with Overweight Rating, Announces Price Target of $38 Benzinga

Jul 2, 2021

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 24, 2021

08:12AM EDT The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO Benzinga

Jun 23, 2021

07:35AM EDT The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway Benzinga

Jun 22, 2021

04:01PM EDT Century Therapeutics Announces Closing of Initial Public Offering GlobeNewswire Inc

08:12AM EDT The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal Benzinga

Jun 18, 2021

12:11PM EDT Century Therapeutics Shares Open For Trade At $19.50; IPO Priced At $20/Share Benzinga

10:41AM EDT Century Therapeutics Shares Indicating $19.50 On 303K Shares Benzinga

09:29AM EDT Century Therapeutics Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10 a.m. EDT; IPO Priced At $20/Share Benzinga

Jun 17, 2021

06:15PM EDT Century Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire Inc

Jun 14, 2021

06:13AM EDT Century Therapeutics Sees Up to 10.6M Share IPO Priced $18-$20/Share Benzinga

.dark-mode .PpPpdm{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .PpPpdm{ color: #333333; background-color: white; border: 2px solid #333333; }IPSCCentury Therapeutics, Inc. Common Stockstock NASDAQ

IPSC
Century Therapeutics, Inc. Common Stock
stock NASDAQ